https://www.selleckchem.com/products/gw-4064.html
Background and purpose Irinotecan, a drug used in colorectal cancer therapy is metabolized by glucuronidation involving different UDP-glucuronosyltransferase (UGT)1A isoforms, which leads to facilitated elimination from the body. Individuals homozygous for the genetic variants UGT1A1*28 (Gilbert syndrome) and UGT1A7*3 are more susceptible to irinotecan drug side effects such as severe diarrhea and leukopenia. Aim of this study was to study the protective effects and active constituents of coffee during irinotecan therapy using humanized
Aimer
Commentaire
Partagez
